 |
|
Surveillance for Recurrent Bladder Cancer Using a Point-of-Care Proteomic Assay
H. Barton Grossman, MD;
Mark Soloway, MD;
Edward Messing, MD;
Giora Katz, MD;
Barry Stein, MD;
Vahan Kassabian, MD;
Yu Shen, PhD
JAMA. 2006;295:299-305.
Context At least 50% of patients with a history of bladder cancer have recurrences, so rigorous surveillance is necessary. Cystoscopy is standard but can fail to detect some bladder cancers, so a urine test is frequently part of the evaluation.
Objective To investigate whether a point-of-care proteomic test that measures the nuclear matrix protein NMP22 in voided urine could improve detection of recurrence during monitoring of patients with a history of bladder cancer.
Design, Setting, and Patients From September 2001 to February 2002, 23 academic, private practice, and hospital facilities in 9 US states prospectively enrolled 668 consecutive patients with a history of bladder cancer in this cross-sectional study. Patients provided a voided urine sample for analysis of NMP22 protein and cytology prior to cystoscopy.
Main Outcome Measures Diagnosis of bladder cancer recurrence, based on cystoscopy with biopsy, was accepted as the reference standard. The performance of the NMP22 test was compared with voided urine cytology as an aid to detection. Testing for the NMP22 tumor marker was conducted in a blinded manner.
Results Bladder cancer was diagnosed in 103 patients. Cystoscopy alone identified 91.3% of the cancers (94/103; 95% confidence interval [CI], 84.1%-95.9%). The combination of cystoscopy with the NMP22 assay detected 99.0% of the malignancies (102/103; 95% CI, 94.7%-100%; P = .005). The NMP22 assay detected 8 of 9 cancers that were not visualized during initial cystoscopy, including 7 that were high-grade. The sensitivity and specificity of the NMP22 test alone were 49.5% (51/103; 95% CI, 39.5%-59.5%) and 87.3% (493/565; 95% CI, 84.2%-89.9%), respectively. Voided cytology detected only 3 of the malignancies missed during initial cystoscopy and did not significantly increase the sensitivity of cystoscopy (94.2%; 95% CI, 87.7%-97.8%; P = .08).
Conclusion The noninvasive point-of-care assay for elevated urinary NMP22 protein can increase the ability to detect recurrent bladder cancer, with test results available during the patient visit.
Author Affiliations: Departments of Urology (Dr Grossman) and Biostatistics and Applied Mathematics (Dr Shen), M. D. Anderson Cancer Center, Houston, Tex; University of Miami School of Medicine, Miami, Fla (Dr Soloway); University of Rochester Medical Center, Rochester, NY (Dr Messing); Lakeshore Urology, Manitowoc, Wis (Dr Katz); Lake City Veterans Administration Hospital, Lake City, Fla (Dr Katz); Rhode Island Hospital, Providence (Dr Stein); Georgia Urology, Atlanta (Dr Kassabian).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED LETTERS
NMP22 and Surveillance for Recurrent Bladder Cancer
Chad T. Wilson
JAMA. 2006;296(1):44-45.
EXTRACT
| FULL TEXT
NMP22 and Surveillance for Recurrent Bladder Cancer
Scott Eggener and Harry Herr
JAMA. 2006;296(1):45.
EXTRACT
| FULL TEXT
NMP22 and Surveillance for Recurrent Bladder Cancer—Reply
H. Barton Grossman
JAMA. 2006;296(1):45-46.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A Novel Set of DNA Methylation Markers in Urine Sediments for Sensitive/Specific Detection of Bladder Cancer
Yu et al.
Clin. Cancer Res. 2007;13:7296-7304.
ABSTRACT
| FULL TEXT
Molecular Markers of Urothelial Cancer and Their Use in the Monitoring of Superficial Urothelial Cancer
Black et al.
JCO 2006;24:5528-5535.
ABSTRACT
| FULL TEXT
A Reagent Resource to Identify Proteins and Peptides of Interest for the Cancer Community: A WORKSHOP REPORT
Haab et al.
Mol. Cell. Proteomics 2006;5:1996-2007.
ABSTRACT
| FULL TEXT
NMP22 and surveillance for recurrent bladder cancer.
Eggener and Herr
JAMA 2006;296:45-45.
FULL TEXT
NMP22 and surveillance for recurrent bladder cancer.
Wilson
JAMA 2006;296:44-45.
FULL TEXT
|
